Table 3.

Outcomes in all patients

Outcomes, % (95% CI)*	GO n = 137	Controls n = 548	P Value
VOD/SOS
Patients who developed	6	22	-
VOD/SOS, n
VOD/SOS at 100 days	4 (1–7)	3 (2–5)	.76
Severe VOD/SOS at 100 days	3 (1–6)	1 (0–2)	.18
Overall survival
100 days	80 (73–86)	81 (78–84)	.81
6 months	66 (58–74)	69 (65–73)	.52
1 year	53 (44–61)	57 (53–61)	.33
3 years	41 (33–49)	42 (38–46)	.83
5 years	38 (30–46)	38 (34–42)	.97
Disease-free survival
1 year	45 (36–53)	49 (45–54)	.31
3 years	34 (26–42)	38 (34–42)	.45
5 years	31 (24–39)	34 (30–38)	.46
Relapse
1 year	40 (32–48)	32 (28–36)	.09
3 years	45 (37–54)	38 (34–42)	.13
5 years	48 (39–56)	40 (36–44)	.10
Nonrelapse mortality
1 year	15 (10–22)	18 (15–22)	.37
3 years	21 (14–28)	24 (21–28)	.34
5 years	21 (15–29)	26 (22–30)	.26

^*From date of transplant.

CI indicates confidence interval; GO, gemtuzumab ozogamicin; VOD/SOS, veno-occlusive disease/sinusoidal obstruction syndrome